AWE Board, Immediate Past President
Executive Director, Venture Capital Worldwide Business Development
Elaine V. Jones, Ph.D. recently joined Pfizer Venture Investments as Executive Director, Venture Capital. She will be responsible for making and managing venture investments for Pfizer. Elaine brings 10 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team.
Most recently, Elaine was a General Partner with the $250M venture fund, EuclidSR Partners. ESR is focused on the life sciences and technology sectors, as well as in areas where those industries converge to enhance drug discovery, development and marketing. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.
Elaine began her private equity career in 1999 at SR One, GlaxoSmithKline’s corporate venture fund, where she managed investments including Adolor, Avantium, Cogent Neurosciences, Descartes Therapeutics, Message Pharmaceuticals, Nucleonics, Scynexis, Therion Biologics and Vicuron.
Prior to SR One, Elaine was a Director of Scientific Licensing for SmithKline Beecham, where she focused on licensing opportunities in arthritis, bone disease, urology and cancer. In her previous research career at SmithKline Beecham, Elaine applied her virology and biotechnology background to animal health vaccine development. She has published numerous scientific articles and was a named inventor on five patents or patent applications.
Elaine has a B.S. from Juniata College and a Ph.D. in Microbiology from the University of Pittsburgh. She conducted post-doctoral research at the National Institutes of Health, in the National Institute of Allergy and Infectious Disease.
Return to Leadership page